 Manali Kamdar
Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 20 | 2025 | 122 | 7.660 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 12 | 2025 | 73 | 3.240 |
Why?
| | Immunotherapy, Adoptive | 17 | 2025 | 321 | 3.240 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 32 | 2025 | 1682 | 3.070 |
Why?
| | Lymphoma, Mantle-Cell | 8 | 2023 | 20 | 2.980 |
Why?
| | Lymphoma, B-Cell | 8 | 2025 | 106 | 2.780 |
Why?
| | Hematopoietic Stem Cell Transplantation | 10 | 2024 | 614 | 2.280 |
Why?
| | Lymphoma | 4 | 2024 | 208 | 2.060 |
Why?
| | Neoplasm Recurrence, Local | 17 | 2025 | 1058 | 1.910 |
Why?
| | Rituximab | 14 | 2025 | 176 | 1.590 |
Why?
| | Immunoconjugates | 5 | 2023 | 114 | 1.180 |
Why?
| | Neoplasms, Second Primary | 2 | 2020 | 116 | 1.170 |
Why?
| | Lymphoma, Follicular | 3 | 2024 | 40 | 1.060 |
Why?
| | Antibodies, Bispecific | 2 | 2024 | 54 | 1.010 |
Why?
| | Antigens, CD19 | 8 | 2025 | 121 | 0.970 |
Why?
| | Bendamustine Hydrochloride | 5 | 2022 | 13 | 0.970 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 801 | 0.910 |
Why?
| | Burkitt Lymphoma | 5 | 2025 | 60 | 0.910 |
Why?
| | Antibodies, Monoclonal | 6 | 2023 | 1430 | 0.890 |
Why?
| | Neutropenia | 2 | 2023 | 146 | 0.880 |
Why?
| | Cancer Vaccines | 1 | 2025 | 172 | 0.850 |
Why?
| | Thrombocytopenia | 2 | 2023 | 198 | 0.840 |
Why?
| | Hodgkin Disease | 5 | 2024 | 138 | 0.820 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2024 | 98 | 0.820 |
Why?
| | Mediastinal Neoplasms | 3 | 2017 | 45 | 0.770 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 2 | 2022 | 13 | 0.730 |
Why?
| | Cyclophosphamide | 7 | 2024 | 247 | 0.690 |
Why?
| | Humans | 76 | 2025 | 136764 | 0.660 |
Why?
| | Antineoplastic Agents | 7 | 2024 | 2122 | 0.660 |
Why?
| | Vincristine | 6 | 2024 | 116 | 0.650 |
Why?
| | Positron-Emission Tomography | 2 | 2018 | 293 | 0.640 |
Why?
| | Doxorubicin | 7 | 2024 | 362 | 0.620 |
Why?
| | Prognosis | 15 | 2024 | 4013 | 0.620 |
Why?
| | Bone Marrow | 3 | 2021 | 286 | 0.600 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2017 | 249 | 0.580 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2025 | 87 | 0.570 |
Why?
| | Lymphoproliferative Disorders | 1 | 2018 | 55 | 0.560 |
Why?
| | Adult | 38 | 2025 | 37630 | 0.550 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2018 | 134 | 0.550 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 19 | 0.540 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 156 | 0.510 |
Why?
| | Aged | 27 | 2025 | 23794 | 0.490 |
Why?
| | Middle Aged | 29 | 2025 | 33228 | 0.470 |
Why?
| | Standard of Care | 3 | 2025 | 72 | 0.460 |
Why?
| | Transplantation, Autologous | 4 | 2023 | 238 | 0.460 |
Why?
| | Cancer Survivors | 1 | 2019 | 280 | 0.450 |
Why?
| | Pyrazines | 3 | 2025 | 90 | 0.420 |
Why?
| | Benzamides | 3 | 2025 | 216 | 0.420 |
Why?
| | Retrospective Studies | 19 | 2025 | 15504 | 0.420 |
Why?
| | Immunotherapy | 4 | 2025 | 640 | 0.370 |
Why?
| | Hematologic Neoplasms | 2 | 2024 | 155 | 0.370 |
Why?
| | Aged, 80 and over | 16 | 2025 | 7585 | 0.360 |
Why?
| | Male | 30 | 2025 | 67309 | 0.350 |
Why?
| | Female | 31 | 2025 | 72787 | 0.340 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5106 | 0.310 |
Why?
| | Cell- and Tissue-Based Therapy | 3 | 2024 | 80 | 0.300 |
Why?
| | Dexamethasone | 2 | 2022 | 368 | 0.300 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 227 | 0.290 |
Why?
| | Kaplan-Meier Estimate | 6 | 2021 | 888 | 0.290 |
Why?
| | Graft vs Host Disease | 3 | 2020 | 248 | 0.290 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2020 | 99 | 0.290 |
Why?
| | Etoposide | 4 | 2024 | 158 | 0.290 |
Why?
| | Transplantation Conditioning | 5 | 2021 | 170 | 0.280 |
Why?
| | Brain Neoplasms | 1 | 2017 | 1235 | 0.280 |
Why?
| | Treatment Outcome | 16 | 2025 | 10744 | 0.280 |
Why?
| | Chlorambucil | 3 | 2025 | 10 | 0.280 |
Why?
| | Medical Oncology | 2 | 2020 | 289 | 0.260 |
Why?
| | Neoplasm, Residual | 2 | 2024 | 133 | 0.250 |
Why?
| | Proportional Hazards Models | 4 | 2023 | 1261 | 0.240 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 41 | 0.220 |
Why?
| | Sulfonamides | 3 | 2024 | 513 | 0.220 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 16 | 0.210 |
Why?
| | Tumor Lysis Syndrome | 1 | 2023 | 8 | 0.210 |
Why?
| | Neoplasm Staging | 4 | 2020 | 1371 | 0.200 |
Why?
| | Treatment Failure | 1 | 2024 | 354 | 0.200 |
Why?
| | Neoplasm Grading | 2 | 2024 | 305 | 0.200 |
Why?
| | Pyrimidines | 2 | 2024 | 470 | 0.190 |
Why?
| | Young Adult | 11 | 2025 | 13129 | 0.190 |
Why?
| | Recurrence | 4 | 2025 | 1055 | 0.190 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 442 | 0.190 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2024 | 622 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 94 | 0.180 |
Why?
| | SEER Program | 2 | 2019 | 218 | 0.180 |
Why?
| | Methotrexate | 1 | 2022 | 260 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2025 | 718 | 0.170 |
Why?
| | Disease Management | 3 | 2021 | 624 | 0.170 |
Why?
| | Piperidines | 1 | 2022 | 206 | 0.170 |
Why?
| | Cisplatin | 1 | 2022 | 320 | 0.170 |
Why?
| | Societies, Medical | 2 | 2024 | 816 | 0.150 |
Why?
| | Pilot Projects | 1 | 2024 | 1692 | 0.150 |
Why?
| | Risk Factors | 4 | 2023 | 10326 | 0.150 |
Why?
| | Antiviral Agents | 2 | 2021 | 739 | 0.150 |
Why?
| | Pyrazoles | 1 | 2022 | 423 | 0.150 |
Why?
| | Prednisone | 3 | 2024 | 239 | 0.150 |
Why?
| | Thiotepa | 1 | 2018 | 20 | 0.150 |
Why?
| | Herpes Zoster | 1 | 2022 | 316 | 0.140 |
Why?
| | Leukemia, Hairy Cell | 1 | 2017 | 7 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1231 | 0.140 |
Why?
| | Leukemia, B-Cell | 1 | 2017 | 13 | 0.140 |
Why?
| | Radiopharmaceuticals | 1 | 2018 | 177 | 0.140 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 288 | 0.130 |
Why?
| | Prednisolone | 1 | 2017 | 82 | 0.130 |
Why?
| | Adolescent | 7 | 2025 | 21382 | 0.130 |
Why?
| | Symptom Assessment | 1 | 2018 | 128 | 0.130 |
Why?
| | ROC Curve | 1 | 2018 | 545 | 0.130 |
Why?
| | HIV Infections | 2 | 2021 | 2828 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2017 | 303 | 0.130 |
Why?
| | United States | 10 | 2024 | 14691 | 0.120 |
Why?
| | Survivors | 1 | 2019 | 487 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 234 | 0.120 |
Why?
| | Disease-Free Survival | 3 | 2021 | 685 | 0.120 |
Why?
| | Survival Analysis | 4 | 2020 | 1321 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1990 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 800 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1462 | 0.110 |
Why?
| | Survival Rate | 3 | 2025 | 1962 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 889 | 0.100 |
Why?
| | Incidence | 1 | 2020 | 2792 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2018 | 649 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 233 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2019 | 1982 | 0.090 |
Why?
| | Europe | 2 | 2024 | 413 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 934 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2711 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2023 | 139 | 0.090 |
Why?
| | Gene Rearrangement | 2 | 2021 | 149 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2019 | 6033 | 0.070 |
Why?
| | Remission Induction | 2 | 2020 | 288 | 0.070 |
Why?
| | Immunophenotyping | 2 | 2020 | 318 | 0.070 |
Why?
| | Transplantation, Homologous | 2 | 2020 | 415 | 0.070 |
Why?
| | Infant | 3 | 2019 | 9398 | 0.070 |
Why?
| | Child, Preschool | 3 | 2019 | 11000 | 0.060 |
Why?
| | Clarithromycin | 2 | 1997 | 28 | 0.060 |
Why?
| | Acrylamides | 1 | 2024 | 57 | 0.060 |
Why?
| | Maximum Tolerated Dose | 1 | 2024 | 199 | 0.050 |
Why?
| | Lactate Dehydrogenases | 1 | 2023 | 5 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2024 | 102 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2489 | 0.050 |
Why?
| | Myelodysplastic Syndromes | 1 | 2024 | 134 | 0.050 |
Why?
| | North America | 1 | 2023 | 312 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 204 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1272 | 0.050 |
Why?
| | Retreatment | 1 | 2022 | 72 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2023 | 176 | 0.050 |
Why?
| | Bleomycin | 1 | 2023 | 247 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 1 | 2025 | 664 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2022 | 105 | 0.050 |
Why?
| | Indoles | 1 | 2024 | 410 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 121 | 0.040 |
Why?
| | Consensus | 1 | 2024 | 678 | 0.040 |
Why?
| | Child | 3 | 2019 | 21822 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5701 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 310 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2020 | 90 | 0.040 |
Why?
| | Organizations, Nonprofit | 1 | 2020 | 16 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2024 | 1141 | 0.040 |
Why?
| | Australia | 1 | 2021 | 313 | 0.040 |
Why?
| | Canada | 1 | 2021 | 417 | 0.040 |
Why?
| | Central Nervous System | 1 | 2021 | 258 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1062 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2018 | 79 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 22 | 0.040 |
Why?
| | Vidarabine | 1 | 2018 | 33 | 0.040 |
Why?
| | Comorbidity | 1 | 2023 | 1614 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 78 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 327 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 188 | 0.040 |
Why?
| | Cytodiagnosis | 1 | 2017 | 33 | 0.030 |
Why?
| | Lymphocytes | 1 | 2020 | 393 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.030 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2017 | 83 | 0.030 |
Why?
| | Mutation | 2 | 2020 | 3946 | 0.030 |
Why?
| | Chronic Disease | 1 | 2023 | 1784 | 0.030 |
Why?
| | Tonsillitis | 1 | 1997 | 8 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2020 | 489 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2021 | 1507 | 0.030 |
Why?
| | Pharyngitis | 1 | 1997 | 26 | 0.030 |
Why?
| | Penicillins | 1 | 1997 | 58 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 1997 | 45 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 496 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 142 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2016 | 119 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2017 | 224 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1733 | 0.030 |
Why?
| | Streptococcal Infections | 1 | 1997 | 151 | 0.030 |
Why?
| | Radiotherapy | 1 | 2015 | 201 | 0.030 |
Why?
| | Propensity Score | 1 | 2016 | 289 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2016 | 229 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 916 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1044 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1481 | 0.030 |
Why?
| | Amoxicillin | 1 | 1993 | 30 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 1316 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1500 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1613 | 0.020 |
Why?
| | Otitis Media | 1 | 1993 | 165 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2878 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7572 | 0.020 |
Why?
| | Registries | 1 | 2016 | 2015 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1997 | 1798 | 0.020 |
Why?
| | Time Factors | 1 | 2015 | 6806 | 0.010 |
Why?
| | Suspensions | 1 | 1993 | 36 | 0.010 |
Why?
| | Intestinal Absorption | 1 | 1993 | 102 | 0.010 |
Why?
| | Family Practice | 1 | 1997 | 462 | 0.010 |
Why?
| | Single-Blind Method | 1 | 1993 | 282 | 0.010 |
Why?
| | Administration, Oral | 1 | 1993 | 813 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 1004 | 0.010 |
Why?
| | Body Weight | 1 | 1993 | 985 | 0.000 |
Why?
|
|
Kamdar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|